Cargando…
The Maximum-Tolerated Dose and Pharmacokinetics of a Novel Chemically Modified Curcumin in Rats
PURPOSE: CMC 2.24, a chemically modified curcumin, was developed as a novel, pleiotropic MMP-inhibitor to treat various inflammatory/collagenolytic diseases including periodontitis. To date, this compound has shown efficacy in vitro, in cell culture, and in vivo (oral administration) in mice, rats a...
Autores principales: | Bhatt, Heta Dinesh, McClain, Steve A, Lee, Hsi-Ming, Zimmerman, Thomas, Deng, Jie, Johnson, Francis, Gu, Ying, Golub, Lorne M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842656/ https://www.ncbi.nlm.nih.gov/pubmed/35173493 http://dx.doi.org/10.2147/JEP.S341927 |
Ejemplares similares
-
Chemically-Modified Curcumin 2.24: A Novel Systemic Therapy for Natural Periodontitis in Dogs
por: Deng, Jie, et al.
Publicado: (2020) -
A novel modified-curcumin 2.24 resolves inflammation by promoting M2 macrophage polarization
por: Deng, Jie, et al.
Publicado: (2023) -
A Novel Chemically Modified Curcumin “Normalizes” Wound-Healing in Rats with Experimentally Induced Type I Diabetes: Initial Studies
por: Zhang, Yazhou, et al.
Publicado: (2016) -
Inhibition of anthrax lethal factor by curcumin and chemically modified curcumin derivatives
por: Antonelli, Anthony C., et al.
Publicado: (2014) -
Enhanced efficacy of chemically modified curcumin in experimental periodontitis: systemic implications
por: Wang, Howard H, et al.
Publicado: (2019)